Vaccination against Group B streptococcus

Expert Review of Vaccines

Volumn 4, Issue 2, 2005, Pages 207-218

  Heath, Paul T ^a   Feldman, Robert G ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Conjugate vaccine; Group B streptococcus; Mucosal vaccine; Protein vaccine; Streptococcus agalactiae; Vaccine

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; ANTIGEN; B7 ANTIGEN; BACTERIAL POLYSACCHARIDE; BACTERIAL PROTEIN; C5A PEPTIDASE; CAPSULAR CONJUGATE VACCINE; CARBOHYDRATE; CARRIER PROTEIN; CD28 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD86 ANTIGEN; CEPHALOSPORIN DERIVATIVE; COLONY STIMULATING FACTOR; DIPHTHERIA TOXIN; ENOLASE; EPITOPE; GLUTAMATE AMMONIA LIGASE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HAPTOCORRIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN BINDING FACTOR; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; LAMININ BINDING PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MEMBRANE PROTEIN; MENINGOCOCCUS VACCINE; MICROSPHERE; OLIGODEOXYNUCLEOTIDE; PENICILLIN DERIVATIVE; PENTOXIFYLLINE; PEPTIDASE; PNEUMOCOCCUS VACCINE; PROTEIN; PROTEIN C; PROTEIN C ALPHA; PROTEIN C BETA; RIB PROTEIN; SIALIC ACID; STREPTOCOCCUS VACCINE; SURFACE IMMUNOGENIC PROTEIN; TETANUS TOXOID; UNCLASSIFIED DRUG;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL MEMBRANE; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATION; BLOOD CULTURE; CONJUGATE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HAEMOPHILUS INFLUENZAE; HUMAN; INFECTION PREVENTION; NEISSERIA MENINGITIDIS; NEWBORN INFECTION; NONHUMAN; PERINATAL INFECTION; PRACTICE GUIDELINE; PREMATURITY; PRENATAL SCREENING; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEROTYPE; STILLBIRTH; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS INFECTION; THIRD TRIMESTER PREGNANCY; VACCINATION; VERTICAL TRANSMISSION;

HUMANS; INFANT; STREPTOCOCCAL INFECTIONS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS AGALACTIAE; VACCINATION;

EID: 17144399556     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.4.2.207     Document Type: Review

References (89)

1. Nocard M. Sur une mammite contagieuse des vaches laitieres. Ann. Inst. Pasteur 1, 109-127 (1887).
2. Fry R. Fatal infections by hemolytic streptococcus Group B. Lancet 1, 199-201 (1938).
3. Lancefield R, Hare R. The serological differentiation of pathogenic and nonpathogenic strains of hemolytic streptococci from parturient women. J. Exp. Med. 61, 335-349 (1935).
4. Baker CJ, Barrett FF, Gordon RC, Yow MD. Suppurative meningitis due to streptococci of Lancefield Group B: a study of 33 infants. J. Pediatr. 82(4), 724-729 (1973).
5. Weisner AM, Johnson AP, Lamagni TL et al. Characterization of Group B streptococci recovered from infants with invasive disease in England and Wales. Clin. Infect. Dis. 38(9), 1203-1208 (2004).
6. Zaleznik DF, Rench MA, Hillier S et al. Invasive disease due to Group B streptococcus in pregnant women and neonates from diverse population groups. Clin. Infect. Dis. 30(2), 276-281 (2000).
7. Harrison LH, Elliott JA, Dwyer DM et al. Serotype distribution of invasive Group B streptococcal isolates in Maryland: implications for vaccine formulation. Maryland Emerging Infections Program. Clin. Infect. Dis. 177(4), 998-1002 (1998).
8. Edwards M, Baker C. Streptococcus agalactiae (Group B streptococcus). Mandell G, Bennett J, Dolin R (Eds). Churchill Livingstone, PA, USA (2000).
9. Farley MM. Group B streptococcal infection in older patients. Spectrum of disease and management strategies. Drugs Aging 6(4), 293-300 (1995).
10. Amaya RA, Baker CJ, Keitel WA, Edwards MS. Healthy elderly people lack neutrophil-mediated functional activity to Type V Group B streptococcus. J. Am. Geriatr. Soc. 52(1), 46-50 (2004).
11. Berg S, Trollfors B, Lagergard T, Zackrisson G, Claesson BA. Serotypes and clinical manifestations of Group B streptococcal infections in western Sweden. Clin. Microbiol. Infect. 6(1), 9-13 (2000).
12. Schwartz B, Schuchat A, Oxtoby MJ et al. Invasive Group B streptococcal disease in adults. A population-based study in metropolitan Atlanta. JAMA 266(8), 1112-1114 (1991).
13. Madhi SA, Radebe K, Crewe-Brown H et al. High burden of invasive Streptococcus agalactiae disease in South African infants. Ann. Trop. Paediatr. 23(1), 15-23 (2003).
14. Heath PT, Balfour G, Weisner AM et al. Group B streptococcal disease in UK and Irish infants younger than 90 days. Lancet 363(9405), 292-294 (2004).
15. Luck S, Torny M, d'Agapeyeff K et al. Estimated early onset Group B streptococcal neonatal disease. Lancet 361(9373), 1953-1954 (2003).
16. Aavitsland P, Hoiby EA, Lystad A. Systemic Group B streptococcal disease in neonates and young infants in Norway 1985-1994. Acta Paediatr. 85(1), 104-105 (1996).
17. Kalliola S, Vuopio-Varkila J, Takala AK, Eskola J. Neonatal Group B streptococcal disease in Finland: a ten-year nationwide study. Pediatr. Infect. Dis. J. 18(9), 806-810 (1999).
18. Isaacs D, Royle JA. Intrapartum antibiotics and early onset neonatal sepsis caused by Group B streptococcus and by other organisms in Australia. Australasian Study Group for Neonatal Infections. Pediatr. Infect. Dis. J. 18(6), 524-528 (1999).
19. Schrag SJ, Zywicki S, Farley MM et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N. Engl. J. Med. 342(1), 15-20 (2000).
20. Centers for Disease Control and Prevention. Prevention of perinatal Group B streptococcal disease: a public health perspective. MMWR Recomm Rep. 45(RR-7), 1-24 (1996).
21. Bedford H, de Louvois J, Halket S et al. Meningitis in infancy in England and Wales: follow-up at age 5 years. BMJ 323(7312), 533-536 (2001).
22. Modi N, Carr R. Promising stratagems for reducing the burden of neonatal sepsis. Arch. Dis. Child Fetal Neonatal Ed. 83(2), F150-F153 (2000).
23. Smaill F. Intrapartum antibiotics for Group B streptococcal colonisation. Cochrane Database Syst. Rev. (2), CD00015 (2000).
24. Benitz WE, Gould JB, Druzin ML. Preventing early onset Group B streptococcal sepsis: strategy development using decision analysis. Pediatrics 103(6), E76 (1999).
25. Schrag SJ, Zell ER, Lynfield R et al. A population-based comparison of strategies to prevent early onset Group B streptococcal disease in neonates. N. Engl. J. Med. 347(4), 233-239 (2002). An attempt to evaluate and compare the main intrapartum antibiotic prophylaxis (LAP)-based strategies for prevention.
26. Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A. Prevention of perinatal Group B streptococcal disease. Revised guidelines from CDC. MMWR Recomm. Rep. 51(RR-11), 1-22 (2002). The rationale for the current US approach to prevention.
27. Schuchat A, Zywicki SS, Dinsmoor MJ et al. Risk factors and opportunities for prevention of early onset neonatal sepsis: a multicenter case-control study. Pediatrics 105(1), 21-26 (2000).
28. Moore MR, Schrag SJ, Schuchat A. Effects of intrapartum antimicrobial prophylaxis for prevention of Group B streptococcal disease on the incidence and ecology of early onset neonatal sepsis. Lancet Infect. Dis. 3(4), 201-213 (2003). Analysis of evidence for the emergence of antibiotic resistance following widespread use of IAP.
29. Mohle-Boetani JC, Schuchat A, Plikaytis BD, Smith JD, Broome CV. Comparison of prevention strategies for neonatal Group B streptococcal infection. A population-based economic analysis. JAMA 270(12), 1442-1448 (1993).
30. Baker CJ, Kasper DL. Correlation of maternal antibody deficiency with susceptibility to neonatal Group B streptococcal infection. N. Engl. J. Med. 294(14), 753-756 (1976). One of the first studies to demonstrate a relationship between antibody concentrations and susceptibility to disease.
31. Feldman RG, Ferrante A. Prevalence of anti-Group B streptococcal Type III capsular IgG antibodies in the United Kingdom and an analysis of their specific IgG subclasses. J. Infect. Dis. 162(4), 883-887 (1990).
32. Lin FY, Philips JB, Azimi PH et al. Level of maternal antibody required to protect neonates against early onset disease caused by Group B streptococcus Type Ia: a multicenter, seroepidemiology study. J. Infect. Dis. 184(8), 1022-1028 (2001). Provides a rationale for the licensing of capsular conjugate vaccines based on serologic correlates of protection.
33. Lin FY, Weisman LE, Azimi PH et al. Level of maternal IgG anti-Group B streptococcus Type III antibody correlated with protection of neonates against early onset disease caused by this pathogen. J. Inject. Dis. 190(5), 928-934 (2004). Provides a rationale for the licensing of capsular conjugate vaccines based on serologic correlates of protection.
34. Baker CJ, Rench MA, Edwards MS et al. Immunization of pregnant women with a polysaccharide vaccine of Group B streptococcus. N. Engl. J. Med. 319(18), 1180-1185 (1988). First study of a Group B streptococcus (GBS) vaccine in pregnant women.
35. Wilkinson HW, Eagon RG. Type-specific antigens of Group B Type Ic streptococci. Infect. Immun. 4(5), 596-604 (1971).
36. Russell-Jones GJ, Gotschlich EC, Blake MS. A surface receptor specific for human IgA on Group B streptococci possessing the Ibc protein antigen. J. Exp. Med. 160(5), 1467-1475 (1984).
37. Stalhammar-Carlemalm M, Stenberg L, Lindahl G. Protein rib: a novel Group B streptococcal cell surface protein that confers protective immunity and is expressed by most strains causing invasive infections. J. Exp. Med. 177(6), 1593-1603 (1993).
38. Brodeur BR, Boyer M, Charlebois I et al. Identification of Group B streptococcal Sip protein, which elicits cross-protective immunity. Infect. Immun. 68(10), 5610-5618 (2000).
39. Hill HR, Bohnsack JF, Morris EZ et al. Group B streptococci inhibit the chemotactic activity of the fifth component of complement. J. Immunol. 141(10), 3551-3556 (1988).
40. Spellerberg B, Rozdzinski E, Martin S et al. Lmb, a protein with similarities to the LraI adhesin family, mediates attachment of Streptococcus agalactiae to human laminin. Infect. Immun. 67(2), 871-878 (1999).
41. Lancefield R, Perlmann G. Preparation and properties of a protein (R antigen) occurring in streptococci of Group A, Type 28 and in certain streptococci of other serological groups. J. Exp. Med. 96, 83-97 (1952).
42. Suvorov AN, Flores AE, Ferrieri P. Cloning of the glutamine synthetase gene from Group B streptococci. Infect. Immun. 65(1), 191-196 (1997).
43. Pancholi V, Fischetti VA. α-enolase, a novel strong plasmin(ogen)-binding protein on the surface of pathogenic streptococci. J. Biol. Chem. 273(23), 14503-14515 (1998).
44. Hughes MJ, Moore JC, Lane JD et al. Identification of major outer surface proteins of Streptococcus agalactiae. Infect. Immun. 70(3), 1254-1259 (2002).
45. Seepersaud R, Hanniffy SB, Mayne P et al. Characterization of a novel leucine-rich repeat protein antigen from Group B streptococci that elicits protective immunity. Infect. Immun. 73(3), 1671-1683 (2005).
46. Lachenauer CS, Kasper DL, Shimada J et al. Serotypes VI and VIII predominate among Group B streptococci isolated from pregnant Japanese women. J. Infect. Dis. 179(4), 1030-1033 (1999).
47. Hunter SK, Andracki ME, Krieg AM. Biodegradable microspheres containing Group B streptococcus vaccine: immune response in mice. Am. J. Obstet. Gynecol. 185(5), 1174-1179 (2001).
48. Guttormsen HK, Sharpe AH, Chandraker AK et al. Cognate stimulatory B-cell-T-cell interactions are critical for T-cell help recruited by glycoconjugate vaccines. Infect. Immun. 67(12), 6375-6384 (1999).
49. Kasper DL, Paoletti LC, Wessels MR et al. Immune response to Type III Group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J. Clin. Invest. 98(10), 2308-2314 (1996).
50. Baker CJ, Edwards MS. Group B streptococcal conjugate vaccines. Arch. Dis. Child. 88(5), 375-378 (2003). Review of the development of GBS capsular conjugate vaccines.
51. Paoletti LC, Kasper DL. Conjugate vaccines against Group B streptococcus types IV and VII. J. Infect. Dis. 186(1), 123-126 (2002).
52. Paoletti LC, Pinel J, Johnson KD et al. Synthesis and preclinical evaluation of glycoconjugate vaccines against Group B streptococcus types VI and VIII. J. Infect. Dis. 180(3), 892-895 (1999).
53. Baker CJ, Rench MA, McInnes P. Immunization of pregnant women with Group B streptococcal Type III capsular polysaccharide-tetanus toxoid conjugate vaccine. Vaccine 21 (24), 3468-3472 (2003). First study of a GBS capsular conjugate vaccine in pregnant women.
54. Palazzi DL, Rench MA, Edwards MS, Baker CJ. Use of Type V Group B streptococcal conjugate vaccine in adults 65-85 years old. J. Infect. Dis. 190(3), 558-564 (2004).
55. Paoletti LC, Rench MA, Kasper DL et al. Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of Group B streptococcal Type III conjugate vaccines. Infect. Immun. 69(11), 6696-6701 (2001).
56. Barington T, Skettrup M, Juul L, Heilmann C. Nonepitope-specific suppression of the antibody response to Haemophilus influenzae type b conjugate vaccines by preimmunization with vaccine components. Infect. Immun. 61(2), 432-438 (1993).
57. Baker CJ, Paoletti LC, Rench MA et al. Immune response of healthy women to 2 different Group B streptococcal Type V capsular polysaccharide-protein conjugate vaccines. J. Infect. Dis. 189(6), 1103-1112 (2004).
58. Paoletti LC, Peterson DL, Legmann R, Collier RJ. Preclinical evaluation of Group B streptococcal polysaccharide conjugate vaccines prepared with a modified diphtheria toxin and a recombinant duck hepatitis B core antigen. Vaccine 20(3-4), 370-376 (2001).
59. Paoletti LC, Wessels MR, Rodewald AK et al. Neonatal mouse protection against infection with multiple Group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine. Inject. Immun. 62(8), 3236-3243 (1994).
60. Baker CJ, Rench MA, Fernandez M et al. Safety and immunogenicity of a bivalent Group B streptococcal conjugate vaccine for serotypes II and III. J. Infect. Dis. 188(1), 66-73 (2003).
61. Cheng Q, Debol S, Lam H et al. Immunization with C5a peptidase or peptidase Type III polysaccharide conjugate vaccines enhances clearance of Group B Streptococci from lungs of infected mice. Infect. Immun. 70(11), 6409-6415 (2002).
62. Maeland JA, Bevanger L, Lyng RV. Antigenic determinants of alpha-like proteins of Streptococcus agalactiae. Clin. Diagn. Lab. Immunol. 11(6), 1035-1039 (2004).
63. Gravekamp C, Kasper DL, Paoletti LC, Madoff LC. αC protein as a carrier for Type III capsular polysaccharide and as a protective protein in Group B streptococcal vaccines. Infect. Immun. 67(5), 2491-2496 (1999).
64. Madoff LC, Paoletti LC, Tai JY, Kasper DL. Maternal immunization of mice with Group B streptococcal Type III polysaccharide-β C protein conjugate elicits protective antibody to multiple serotypes. J. Clin. Invest. 94(1), 286-292 (1994).
65. Magliani W, Polonelli L, Conti S et al. Neonatal mouse immunity against Group B streptococcal infection by maternal vaccination with recombinant anti-idiotypes. Nature Med. 4(6), 705-709 (1998).
66. Ferrieri P, Hillier SL, Krohn MA et al. Characterization of vaginal and rectal colonization with multiple serotypes of Group B streptococci using multiple colony picks. Indian J. Med. Res. 119(Suppl.), 208-212 (2004).
67. Dagan R, Givon-Lavi N, Zamir O et al. Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J. Infect. Dis. 185(7), 927-936 (2002).
68. Baker CJ, Kasper DL, Davis CE. Immunochemical characterization of the native Type III polysaccharide of Group B streptococcus. J. Exp. Med. 143(2), 258-270 (1976).
69. Feldman RG, Rijkers GT, Hamel ME, David S, Zegers BJ. The Group B streptococcal capsular carbohydrate: immune response and molecular mimicry. Adv. Exp. Med. Biol. 435, 261-269 (1998).
70. Hayrinen J, Pelkonen S, Finne J. Structural similarity of the type-specific Group B streptococcal polysaccharides and the carbohydrate units of tissue glycoproteins: evaluation of possible cross reactivity. Vaccine 7(3), 217-224 (1989).
71. Gravekamp C, Horensky DS, Michel JL, Madoff LC. Variation in repeat number within the alpha C protein of Group B streptococci alters antigenicity and protective epitopes. Infect. Immun. 64(9), 3576-3583 (1996).
72. Larsson C, Holmgren J, Lindahl G, Bergquist C. Intranasal immunization of mice with Group B streptococcal protein rib and cholera toxin B subunit confers protection against lethal infection. Inject. Immun. 72(2), 1184-1187 (2004).
73. Madoff LC, Michel JL, Gong EW, Rodewald AK, Kasper DL. Protection of neonatal mice from Group B streptococcal infection by maternal immunization with βC protein. Infect. Immun. 60(12), 4989-4994 (1992).
74. Berner R, Bender A, Rensing C, Forster J, Brandis M. Low prevalence of the immunoglobulin A-binding β-antigen of the C protein among Streptococcus agalactiae isolates causing neonatal sepsis. Eur. J. Clin. Microbiol. Infect. Dis. 18(8), 545-550 (1999).
75. Hughes MJ, Wilson R, Moore JC et al. Novel protein vaccine candidates against Group B streptococcal infection identified using alkaline phosphatase fusions. FEMS Microbiol. Lett. 222(2), 263-271 (2003).
76. Glaser P, Rusniok C, Buchrieser C et al. Genome sequence of Streptococcus agalactiae, a pathogen causing invasive neonatal disease. Mol. Microbiol. 45(6), 1499-1513 (2002). The genome of GBS revealed.
77. Hordnes K, Tynning T, Kvam AI, Jonsson R, Haneberg B. Colonization in the rectum and uterine cervix with Group B streptococci may induce specific antibody responses in cervical secretions of pregnant women. Infect. Immun. 64(5), 1643-1652 (1996).
78. Hordnes K, Tynning T, Brown TA, Haneberg B, Jonsson R. Nasal immunization with Group B streptococci can induce high levels of specific IgA antibodies in cervicovaginal secretions of mice. Vaccine 15(11), 1244-1251 (1997).
79. Shen X, Lagergard T, Yang Y et al. Preparation and preclinical evaluation of experimental Group B streptococcus Type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization. Vaccine 19(7-8), 850-861 (2000).
80. Borrow R, Andrews N, Goldblatt D, Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect. Immun. 69(3), 1568-1573 (2001).
81. Kasper DL, Wessels MR, Guttormsen HK et al. Measurement of human antibodies to Type III Group B streptococcus. Infect. Immun. 67(8), 4303-4305 (1999).
82. Brent RL. Immunization of pregnant women: reproductive, medical and societal risks. Vaccine 21(24), 3413-3421 (2003). Excellent review of the issues around vaccination in pregnancy.
83. Atkinson WL, Pickering LK, Schwartz B et al. General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). MMWR Recomm. Rep. 51(RR-2), 1-35 (2002).
84. Booy R, Hodgson SA, Slack MP et al. Invasive Haemophilus influenzae type b disease in the Oxford region (1985-1991). Arch. Dis. Child 69(2), 225-228 (1993).
85. Tudor-Williams G, Frankland J, Isaacs D et al. Haemophilia influenzae type b disease in the Oxford region. Arch. Dis. Child. 64(4), 517-519 (1989).
86. Chief Medical Officer. Introduction of immunisation against Group C meningococcal infection. Department of Health, UK, (1999).
87. Baker CJ, Paoletti LC, Wessels MR et al. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for Group B streptococcal types Ia and Ib. J. Infect. Dis. 179(1), 142-150 (1999).
88. Baker CJ, Paoletti LC, Rench MA et al. Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for Type II Group B streptococcus in healthy women. J. Infect. Dis. 182(4), 1129-1138 (2000).
89. Bevanger L. Ibc proteins as serotype markers of Group B streptococci. Acta Pathol. Microbiol. Immunol. Scand. B 91(4), 231-234 (1983).